# Nohla Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nohla-therapeutics

- Industry: Biotechnology
- Headquarters: Seattle, US
- Website: www.nohlatherapeutics.com
- Total disclosed funding: $100M
- Latest round: Series B (Jul 11, 2018)
- Investors on record: 10

## About

Nohla Therapeutics Inc. is dedicated to developing innovative therapeutic solutions for hematology and oncology, focusing on advanced cell therapies designed to enhance patient recovery post-stem cell transplants.Founded in 2015 and headquartered in Seattle, US, Nohla Therapeutics Inc. specializes in cell therapies that improve recovery for patients with blood-related disorders. The company raised USD 11.000 mn in SERIES B funding on July 11, 2018, primarily from Premier Partners, Schroders Capital, and The University of Tokyo Edge Capital Partners. There are no recorded pivots or changes in business strategy since its inception, and it has completed a total of 4 deals to date.Nohla Therapeutics specializes in innovative therapeutic solutions aimed at addressing unmet medical needs in the fields of hematology and oncology. The company's flagship product is an advanced cell therapy designed to enhance the recovery of patients undergoing stem cell transplants, particularly those affected by blood-related disorders. This therapy functions by leveraging proprietary techniques to improve the proliferation and efficacy of stem cells, thereby aiding in quicker and more effective patient recovery. Nohla Therapeutics primarily serves hospitals and specialized healthcare facilities, focusing on regions with significant healthcare infrastructure, including North America and parts of Europe. Their client base comprises healthcare professionals, oncologists, and hematologists who are instrumental in administering these therapies to patients facing critical health challenges.Nohla Therapeutics generates revenue through a structured model that includes partnerships with healthcare institutions and direct engagements with medical professionals. Transactions are typically structured around treatment protocols, with healthcare providers paying fees for each patient treatment cycle utilizing the company's therapeutic products. The pricing plans reflect the complex nature of cell therapies, considering factors such as treatment duration and the specific medical conditions being addressed. This model allows for both direct-to-consumer engagement in specialized cases and B2B transactions with healthcare providers, ensuring a steady flow of revenue as the demand for advanced therapeutic options continues to grow within the healthcare industry.Nohla Therapeutics plans to leverage its recent Series B funding of USD 11.000 mn, part of a larger USD 56.000 mn deal, to accelerate the development of new therapeutic products. The company aims to expand its market presence in Europe and Asia by 2025, targeting regions with unmet healthcare needs for advanced cell therapies. The funding will support research and development initiatives, enhancing their product pipeline as they work towards improving patient outcomes in hematology and oncology.

## Funding rounds

- Series B, Jul 11, 2018, $11M — Schroders Capital, University of Tokyo Edge Capital Partners, Premier Partners
- Series B, May 15, 2018, $45M — ARCH Venture Partners, Alexandria Venture Investments, 5AM Ventures, Fidelity Investments, Celgene, AML Biotech Partners
- Series A, Nov 29, 2016, $44M — ARCH Venture Partners, 5AM Ventures, Jagen

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series A, Series B
- 5AM Ventures (https://capitalatlas.ai/funds/5am-ventures) — Series A, Series B
- Jagen — Series A
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series B
- Fidelity Investments (https://capitalatlas.ai/funds/fidelity-investments) — Series B
- Celgene — Series B
- AML Biotech Partners — Series B
- Schroders Capital (https://capitalatlas.ai/funds/schroders-capital) — Series B
- University of Tokyo Edge Capital Partners (https://capitalatlas.ai/funds/university-of-tokyo-edge-capital-partners) — Series B
- Premier Partners (https://capitalatlas.ai/funds/premier-partners) — Series B